Shots: Spark to get exclusive, WW license to develop, manufacture and commercialize CG01 whereas CombiGene will continue to execute aspects of the preclinical program The companies will work together and […]readmore
Tags : Commercialize
Shots: AM-Pharma to receive $23.6M up front, $35.4M in milestones before regulatory submission and ~$230.4M upon submission, NHI price listing & sales milestone along with royalties on sales and a […]readmore
Shots: The agreement follows the NICE recommendation to deliver Leqvio via a population health management approach for high-risk cardiovascular patients across England The NICE recommendation was based on Novartis’s ORION […]readmore
Shots: Wanchunbulin to receive $30M up front, $170M as regulatory and sales milestone & is eligible to receive $15M as equity investment at a pre-money valuation of $560M Hengrui gets […]readmore
Shots: NovaRock to receive $7.5M up front and is eligible to receive ~$633M as development & sales milestones along with royalties on the sales of the licensed products in the […]readmore
Shots: The companies collaborated to form JV to develop, manufacture, and commercialize biosimilars for a global market The collaboration will utilize Cipla and Kemwell’s strengths for product development, clinical development, […]readmore
Shots: RemeGen to receive $200M up front for development and commercialization rights of disitamab vedotin outside of Remegen’s territory & ~$2.4B upon the achievement of milestones across multiple indications along […]readmore
Shots: The companies collaborated to research, develop & commercialize small molecules directed against the GPR75 target with the potential to treat obesity and related co-morbidities The collaboration builds on the […]readmore
Shots: Polpharma reported that its JV with Santo Holding, Bioeq has concluded a commercial partnership with Teva for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis) in the EU, […]readmore
Shots: Seres to receive $175M up front, $125M upon the US FDA’s approval of SER-109 along with ~$225M as a commercial milestone. Seres will be responsible for development & pre-commercialization […]readmore